Jong-Min Kim1,2,3,4, Chung-Gyu Park5,6,7,8,9,10,11. 1. Xenotransplantation Research Center, Seoul National University Graduate School, Seoul, Korea. 2. Institute of Endemic Diseases, Seoul National University Graduate School, Seoul, Korea. 3. Cancer Research Institute, Seoul National University Graduate School, Seoul, Korea. 4. Biomedical Research Institute, Seoul National University Hospital, Seoul, 110-799, Korea. 5. Xenotransplantation Research Center, Seoul National University Graduate School, Seoul, Korea. chgpark@snu.ac.kr. 6. Institute of Endemic Diseases, Seoul National University Graduate School, Seoul, Korea. chgpark@snu.ac.kr. 7. Cancer Research Institute, Seoul National University Graduate School, Seoul, Korea. chgpark@snu.ac.kr. 8. Biomedical Research Institute, Seoul National University Hospital, Seoul, 110-799, Korea. chgpark@snu.ac.kr. 9. Department of Microbiology and Immunology, Seoul National University Graduate School, Seoul, Korea. chgpark@snu.ac.kr. 10. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea. chgpark@snu.ac.kr. 11. Department of Microbiology and Immunology, Department of Biomedical Sciences, Xenotransplantation Research Center, Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro Jongno-gu, Seoul, 110-799, Korea. chgpark@snu.ac.kr.
Abstract
BACKGROUND: The objective of this study was to investigate whether the use of live attenuated varicella zoster virus (VZV) MAV vaccination can efficiently induce VZV antibody production in naive rhesus monkeys as an approach to prevent simian varicella virus (SVV) reactivation in animals immunosuppressed for transplantation studies. RESULTS: Clinically available human VZV vaccine was used to induce the production of anti-VZV antibodies in rhesus monkeys. A vial of the vaccine was subcutaneously injected at 0 week, and the second and third vaccination was performed at 5 and 6 weeks by intratracheal inoculation. The titer of anti-VZV IgG was assessed at 0, 2, 4, 6, and 7 weeks. At 2 weeks, 3/16 were seropositive for VZV IgG. At 6 weeks, 9/16 were shown to be seropositive. At 7 weeks, 16/16 were found to be seropositive. CONCLUSIONS: The VZV vaccine via intratrachael inoculation was shown to induce VZV IgG humoral immunity in rhesus monkeys and may be important immunosuppressed macaques for transplantation studies. Although the humoral immunity produced is an important finding, further studies will be necessary to confirm possible protection and it could protect probably against SVV infection in rhesus monkey.
BACKGROUND: The objective of this study was to investigate whether the use of live attenuated varicella zoster virus (VZV) MAV vaccination can efficiently induce VZV antibody production in naive rhesus monkeys as an approach to prevent simian varicella virus (SVV) reactivation in animals immunosuppressed for transplantation studies. RESULTS: Clinically available humanVZV vaccine was used to induce the production of anti-VZV antibodies in rhesus monkeys. A vial of the vaccine was subcutaneously injected at 0 week, and the second and third vaccination was performed at 5 and 6 weeks by intratracheal inoculation. The titer of anti-VZV IgG was assessed at 0, 2, 4, 6, and 7 weeks. At 2 weeks, 3/16 were seropositive for VZV IgG. At 6 weeks, 9/16 were shown to be seropositive. At 7 weeks, 16/16 were found to be seropositive. CONCLUSIONS: The VZV vaccine via intratrachael inoculation was shown to induce VZV IgG humoral immunity in rhesus monkeys and may be important immunosuppressed macaques for transplantation studies. Although the humoral immunity produced is an important finding, further studies will be necessary to confirm possible protection and it could protect probably against SVV infection in rhesus monkey.
Authors: K E Driscoll; D L Costa; G Hatch; R Henderson; G Oberdorster; H Salem; R B Schlesinger Journal: Toxicol Sci Date: 2000-05 Impact factor: 4.849
Authors: Ivan Gentile; Emanuela Zappulo; Raffaele Bonavolta; Roberta Maresca; Maria Pia Riccio; Antonio Riccardo Buonomo; Giuseppe Portella; Alessandro Settimi; Antonio Pascotto; Guglielmo Borgia; Carmela Bravaccio Journal: In Vivo Date: 2014 Jul-Aug Impact factor: 2.155